Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• Kyverna Therapeutics reported a quarterly loss of $0.63 per share, beating analysts’ expected loss of $0.67 by $0.04.
• Shares rose 1.6% to $8.02 after the earnings release. The stock remains well below its 12-month high of $13.67, with a market capitalization of approximately $487.5 million.
• Analyst sentiment is mixed but leans positive: five analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $30 price target.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.04, FiscalAI reports.

Kyverna Therapeutics Stock Up 1.6%

KYTX traded up $0.13 on Tuesday, hitting $8.02. The company had a trading volume of 657,572 shares, compared to its average volume of 934,387. The stock has a market capitalization of $487.54 million, a price-to-earnings ratio of -2.45 and a beta of 1.93. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The stock has a fifty day moving average price of $8.05 and a 200-day moving average price of $8.48. Kyverna Therapeutics has a 12-month low of $2.80 and a 12-month high of $13.67.

Analyst Ratings Changes

A number of research analysts have commented on KYTX shares. Wall Street Zen downgraded shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. lowered their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors have recently modified their holdings of KYTX. Empowered Funds LLC bought a new position in shares of Kyverna Therapeutics during the 4th quarter worth approximately $169,000. AQR Capital Management LLC acquired a new stake in Kyverna Therapeutics in the first quarter valued at approximately $137,000. Federated Hermes Inc. grew its holdings in Kyverna Therapeutics by 22.2% in the second quarter. Federated Hermes Inc. now owns 44,000 shares of the company's stock worth $135,000 after purchasing an additional 8,000 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Kyverna Therapeutics by 31.1% in the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock worth $132,000 after purchasing an additional 16,267 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Kyverna Therapeutics during the 2nd quarter valued at $107,000. 18.08% of the stock is currently owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source